Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — artichoke leaf and the probiotic component have randomized human support; one ingredient here needs a caution rather than a citation
What Finessa Claims To Be
Finessa is a daily digestive formula sold on the promise of smoother digestion, comfortable regularity, less post-meal heaviness and a more balanced gut. It combines three distinct strategies in one product: bitter, bile-stimulating botanicals; a probiotic and polyphenol component; and a stimulant laxative herb.
Those three do different jobs on different timescales, and they should be judged separately rather than as a single “gut health” claim.
What’s Actually In It
The disclosed components are:
- Dandelion root
- Milk thistle
- Cascara sagrada
- Artichoke leaf
- Turmeric
- Licorice root
- Probiotic blend — 52.5 mg, 5 billion CFU at manufacture, including L. casei, L. acidophilus and L. rhamnosus
- Akkermansia muciniphila — 2 mg
- Polyphenol blend — 1,000 mg
The botanicals share blend totals rather than carrying individual weights, so there is no way to tell how much artichoke leaf or how much cascara you are taking. For the cascara in particular, that is not a trivial gap.
What The Research Shows
According to PubMed, the strongest randomized evidence in this formula belongs to artichoke leaf.
Artichoke leaf beat placebo in a proper multicentre trial. In a six-week, double-blind, randomized controlled trial, 247 patients with functional dyspepsia received either artichoke leaf extract (2 × 320 mg, three times daily) or placebo. Overall symptom improvement was significantly greater with the extract (8.3 ± 4.6 vs 6.7 ± 4.8, p \< 0.01), as was improvement in disease-specific quality of life on the Nepean Dyspepsia Index. Note the dose: nearly 2 grams a day. DOI
It also shifted bowel pattern in people with concurrent IBS. A subset analysis of 208 adults with dyspepsia who also met IBS criteria found a 26.4% fall in IBS incidence after two months, a significant shift in self-reported bowel pattern away from alternating constipation and diarrhoea toward normal, and a 41% drop in total symptom score. This was an open, uncontrolled postal study, so the placebo component is unmeasured — treat it as supporting, not decisive. DOI
The probiotic side has pooled randomized backing for regularity. A systematic review and meta-analysis of 17 randomized controlled trials in 1,256 adults with functional constipation found probiotic-containing products significantly increased stool frequency (weighted mean difference 0.93 bowel movements, 95% CI 0.47–1.40), improved stool consistency, and reduced constipation symptom scores versus placebo. The authors graded the certainty of that evidence as low to very low, with high heterogeneity — an honest caveat worth carrying. DOI
Akkermansia is the interesting, genuinely novel inclusion. In a randomized, double-blind, placebo-controlled pilot, 32 overweight or obese insulin-resistant volunteers took 10¹⁰ A. muciniphila daily for three months. Pasteurized A. muciniphila improved insulin sensitivity by 28.6% (p = 0.002), reduced insulinaemia and lowered total cholesterol by 8.7% (p = 0.02), and was safe and well tolerated. Those are metabolic endpoints, not digestive comfort ones — and it was a proof-of-concept study in 32 people. DOI
Milk thistle’s liver claim did not survive a controlled comparison. In a phase II randomized, double-blind, placebo-controlled trial in 146 patients at risk of non-alcoholic steatohepatitis, a milk thistle combination lowered ALT within the treated groups over 36 weeks — but there was no significant difference in the relative change in ALT or AST between the treatment groups and placebo (p = 0.465 and p = 0.632). Within-group improvement without between-group separation is exactly the pattern that looks like benefit and isn’t. DOI
Cascara sagrada is the one to think hard about. It is a stimulant laxative: its cascarosides are anthraquinone glycosides that work by irritating the colonic wall. Analytical work quantifying cascarosides from Rhamnus purshiana notes that anthraquinone extracts remain commercialised as crude preparations and that long-term side effects are “still relevant,” with glycosylation reducing toxicity relative to free anthraquinones. It works. That is not the same as being suitable for daily indefinite use. DOI
The Honest Verdict
What holds up: Artichoke leaf is the standout — a 247-patient randomized controlled trial for functional dyspepsia is better evidence than most digestive supplements can point to. The probiotic component has pooled randomized support for stool frequency and consistency. Akkermansia is early but real, and its inclusion suggests someone was reading the literature rather than copying a competitor’s label.
What doesn’t: Milk thistle’s hepatoprotective claim failed the between-group test in a 36-week randomized trial. The artichoke evidence sits at roughly 1,900 mg/day, and with the botanicals pooled into an undisclosed blend total there is no way to know if this product is anywhere near that. And cascara is doing work here that users should be aware of: if this product “makes you regular,” a stimulant laxative is a large part of the reason, and stimulant laxatives are designed for short-term use.
Who this makes sense for: Someone with occasional post-meal heaviness and sluggish digestion who wants to try a bitters-plus-probiotic approach for a defined period — weeks, not indefinitely — and who reads the label for the cascara amount first.
Who should skip it: Anyone with inflammatory bowel disease, bowel obstruction or undiagnosed abdominal pain; anyone already using laxatives; anyone pregnant or breastfeeding; anyone with high blood pressure or on potassium-depleting medication (licorice root raises blood pressure and lowers potassium at sustained doses); and anyone looking for a permanent daily habit rather than a short course.
Check current pricing and availability
View Finessa on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your dentist or physician before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed:
- Holtmann G, et al. Aliment Pharmacol Ther. 2003;18(11-12):1099-105. DOI
- Bundy R, et al. J Altern Complement Med. 2004;10(4):667-9. DOI
- Ding F, et al. BMJ Open. 2024;14(1):e074557. DOI
- Depommier C, et al. Nat Med. 2019;25(7):1096-1103. DOI
- Shaker MK, et al. BMC Complement Med Ther. 2025;25(1):8. DOI
- Demarque DP, et al. J Pharm Pharm Sci. 2018;21(1):347-353. DOI